메뉴 건너뛰기




Volumn 22, Issue 129, 2013, Pages 236-243

Immunosuppression for interstitial lung disease in systemic sclerosis

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; AZATHIOPRINE; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE; PREDNISONE; RITUXIMAB; THYMOCYTE ANTIBODY; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 84883314848     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00001813     Document Type: Review
Times cited : (26)

References (71)
  • 1
    • 34248379222 scopus 로고    scopus 로고
    • Clinical risk assessment of organ manifestations in systemic sclerosis: A report from the EULAR Scleroderma Trials And Research group database
    • Walker UA, Tyndall A, Czirják L, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-763.
    • (2007) Ann Rheum Dis , vol.66 , pp. 754-763
    • Walker, U.A.1    Tyndall, A.2    Czirják, L.3
  • 2
    • 0036124419 scopus 로고    scopus 로고
    • Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIRGSSSc)
    • Ferri C, Valentini G, Cozzi F, et al. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIRGSSSc). Medicine (Baltimore) 2002; 81: 139-153.
    • (2002) Medicine (Baltimore) , vol.81 , pp. 139-153
    • Ferri, C.1    Valentini, G.2    Cozzi, F.3
  • 3
    • 0028360565 scopus 로고
    • Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis
    • Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994; 149: 1583-1590.
    • (1994) Am J Respir Crit Care Med , vol.149 , pp. 1583-1590
    • Wells, A.U.1    Cullinan, P.2    Hansell, D.M.3
  • 4
    • 0028130596 scopus 로고
    • Severe restrictive lung disease in systemic sclerosis
    • Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 1994; 37: 1283-1289.
    • (1994) Arthritis Rheum , vol.37 , pp. 1283-1289
    • Steen, V.D.1    Conte, C.2    Owens, G.R.3
  • 5
    • 33745227399 scopus 로고    scopus 로고
    • Cyclophosphamide versus placebo in scleroderma lung disease
    • Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
    • (2006) N Engl J Med , vol.354 , pp. 2655-2666
    • Tashkin, D.P.1    Elashoff, R.2    Clements, P.J.3
  • 6
    • 36249001195 scopus 로고    scopus 로고
    • Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease
    • Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Resp Crit Care Med 2007; 76: 1026-1034.
    • (2007) Am J Resp Crit Care Med , vol.76 , pp. 1026-1034
    • Tashkin, D.P.1    Elashoff, R.2    Clements, P.J.3
  • 7
    • 33845643063 scopus 로고    scopus 로고
    • A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma
    • Hoyles RK, Ellis RW, Wellsbury J, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arhtritis Rheum 2006; 54: 3962-3970.
    • (2006) Arhtritis Rheum , vol.54 , pp. 3962-3970
    • Hoyles, R.K.1    Ellis, R.W.2    Wellsbury, J.3
  • 8
    • 33644870428 scopus 로고    scopus 로고
    • A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis
    • Nadashkevich O, Davis P, Fritzler M, et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheum 2006; 25: 205-212.
    • (2006) Clin Rheum , vol.25 , pp. 205-212
    • Nadashkevich, O.1    Davis, P.2    Fritzler, M.3
  • 9
    • 55749093240 scopus 로고    scopus 로고
    • Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies
    • Nannini C, West CP, Erwin PJ, et al. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arhtritis Res Ther 2008; 10: R124.
    • (2008) Arhtritis Res Ther , vol.10
    • Nannini, C.1    West, C.P.2    Erwin, P.J.3
  • 10
    • 66149100618 scopus 로고    scopus 로고
    • European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: Methods of elaboration and results of systemic literature research
    • Avouac J, Kowal-Bielecka O, Landewé R, et al. European League Against Rheumatism (EULAR) Scleroderma Trials and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systemic literature research. Ann Rheum Dis 2009; 68: 620-628.
    • (2009) Ann Rheum Dis , vol.68 , pp. 620-628
    • Avouac, J.1    Kowal-Bielecka, O.2    Landewé, R.3
  • 11
    • 15644362541 scopus 로고    scopus 로고
    • A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis
    • Guillevin L, Cordier JF, Lhote F, et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997; 40: 2187-2198.
    • (1997) Arthritis Rheum , vol.40 , pp. 2187-2198
    • Guillevin, L.1    Cordier, J.F.2    Lhote, F.3
  • 12
    • 75649109604 scopus 로고    scopus 로고
    • A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis
    • Derk CT, Grace E, Shenin M, et al. A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis. Rheumatology 2009; 48: 1595-1599.
    • (2009) Rheumatology , vol.48 , pp. 1595-1599
    • Derk, C.T.1    Grace, E.2    Shenin, M.3
  • 13
    • 79955788963 scopus 로고    scopus 로고
    • Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis
    • Le EN, Wigely FM, Shah AA, et al. Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2011; 70: 1104-1107.
    • (2011) Ann Rheum Dis , vol.70 , pp. 1104-1107
    • Le, E.N.1    Wigely, F.M.2    Shah, A.A.3
  • 14
    • 33847394965 scopus 로고    scopus 로고
    • Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis
    • Nihtyanova SI, Brough GM, Black CM, et al. Mycophenolate mofetil in diffuse cutaneous systemic sclerosis-a retrospective analysis. Rheumatology 2007; 46: 442-445.
    • (2007) Rheumatology , vol.46 , pp. 442-445
    • Nihtyanova, S.I.1    Brough, G.M.2    Black, C.M.3
  • 15
    • 36349014858 scopus 로고    scopus 로고
    • Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease
    • Zamora AC, Wolters PJ, Collard HR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Resp Med 2008; 102: 150-155.
    • (2008) Resp Med , vol.102 , pp. 150-155
    • Zamora, A.C.1    Wolters, P.J.2    Collard, H.R.3
  • 16
    • 80755163187 scopus 로고    scopus 로고
    • Effect of mycophenolate sodium in scleroderma-related interstitial lung disease
    • Simeó n-Aznar CP, Fonollosa-Plá V, Tolosa-Vilella C, et al. Effect of mycophenolate sodium in scleroderma-related interstitial lung disease. Clin Rheumatol 2011; 30: 1393-1398.
    • (2011) Clin Rheumatol , vol.30 , pp. 1393-1398
    • Simeón-Aznar, C.P.1    Fonollosa-Plá, V.2    Tolosa-Vilella, C.3
  • 17
    • 84878676906 scopus 로고    scopus 로고
    • Enteric-coated mycophenolate sodium for progressive systemic sclerosis a prospective open-label study with CT histography for monitoring of fibrosis
    • Henes JC, Horger M, Amberger C, et al. Enteric-coated mycophenolate sodium for progressive systemic sclerosis a prospective open-label study with CT histography for monitoring of fibrosis. Clin Rheumatol 2013; 32: 673-678.
    • (2013) Clin Rheumatol , vol.32 , pp. 673-678
    • Henes, J.C.1    Horger, M.2    Amberger, C.3
  • 18
    • 34248137269 scopus 로고    scopus 로고
    • A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis
    • Vanthuyne M, Blockmans D, Westhovens R, et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-292.
    • (2007) Clin Exp Rheumatol , vol.25 , pp. 287-292
    • Vanthuyne, M.1    Blockmans, D.2    Westhovens, R.3
  • 19
    • 79952109158 scopus 로고    scopus 로고
    • Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease
    • Koutroumpas A, Ziogas A, Alexiou, et al. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease. Clin Rheumatol 2010; 29: 1167-1168.
    • (2010) Clin Rheumatol , vol.29 , pp. 1167-1168
    • Koutroumpas, A.1    Ziogas, A.2    Alexiou3
  • 20
    • 39449103902 scopus 로고    scopus 로고
    • Effect of mycophenolate mofetil on pulmonary function in Sclerodermaassociated interstitial lung disease
    • Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in Sclerodermaassociated interstitial lung disease. Chest 2008; 133: 455-460.
    • (2008) Chest , vol.133 , pp. 455-460
    • Gerbino, A.J.1    Goss, C.H.2    Molitor, J.A.3
  • 21
    • 33746437403 scopus 로고    scopus 로고
    • Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease
    • Liossis SNC, Bounas A, Anonopoulos AP. Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease. Rheumatology 2006; 45: 1005-1008.
    • (2006) Rheumatology , vol.45 , pp. 1005-1008
    • Liossis, S.N.C.1    Bounas, A.2    Anonopoulos, A.P.3
  • 22
    • 84876918697 scopus 로고    scopus 로고
    • Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease
    • Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. J Rheumatol 2013; 40: 640-646.
    • (2013) J Rheumatol , vol.40 , pp. 640-646
    • Fischer, A.1    Brown, K.K.2    du Bois, R.M.3
  • 23
    • 84864095990 scopus 로고    scopus 로고
    • Treatment of systemic sclerosis complications: What to use when first-line treatment fails-a consensus of systemic sclerosis experts
    • Walker KM, Pope J. Treatment of systemic sclerosis complications: what to use when first-line treatment fails-a consensus of systemic sclerosis experts. Semin Arthritis Rheum 2012; 42: 42-55.
    • (2012) Semin Arthritis Rheum , vol.42 , pp. 42-55
    • Walker, K.M.1    Pope, J.2
  • 24
    • 44949238111 scopus 로고    scopus 로고
    • Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: A retrospective multicenter open-label study
    • Bérezné A, Ranque B, Valeyre D, et al. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study. J Rheumatol 2008; 35: 1064-1072.
    • (2008) J Rheumatol , vol.35 , pp. 1064-1072
    • Bérezné, A.1    Ranque, B.2    Valeyre, D.3
  • 25
    • 34648822788 scopus 로고    scopus 로고
    • Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy
    • Paone C, Chiarolanza I, Cuomo G, et al. Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy. Clin Exp Rheumatol 2007; 25: 613-616.
    • (2007) Clin Exp Rheumatol , vol.25 , pp. 613-616
    • Paone, C.1    Chiarolanza, I.2    Cuomo, G.3
  • 26
    • 0029867337 scopus 로고    scopus 로고
    • Comparison of methotrexate with placebo in the treatment of systemic sclerosis: A 24 week randomized double-blind trial, followed by a 24 week observational trial
    • Van den Hoogen FH, Boerbooms AM, Swaak AJ, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol 1996; 35: 364-372.
    • (1996) Br J Rheumatol , vol.35 , pp. 364-372
    • van den Hoogen, F.H.1    Boerbooms, A.M.2    Swaak, A.J.3
  • 27
    • 0034970031 scopus 로고    scopus 로고
    • A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma
    • Pope JE, Bellamy N, Seibold JR, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-1358.
    • (2001) Arthritis Rheum , vol.44 , pp. 1351-1358
    • Pope, J.E.1    Bellamy, N.2    Seibold, J.R.3
  • 28
    • 0031684342 scopus 로고    scopus 로고
    • Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis
    • Steen VD, Medsger TA Jr. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998; 41: 1613-1619.
    • (1998) Arthritis Rheum , vol.41 , pp. 1613-1619
    • Steen, V.D.1    Medsger Jr., T.A.2
  • 29
    • 37749049969 scopus 로고    scopus 로고
    • Group Français de Recherche sur le Sclérodermie (GFRS). Mortality and risk factors of scleroderma renal crisis: A French retrospective study of 50 patients
    • Teixeira L, Mouthon L, Mahr A, et al. Group Français de Recherche sur le Sclérodermie (GFRS). Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008; 67: 110-116.
    • (2008) Ann Rheum Dis , vol.67 , pp. 110-116
    • Teixeira, L.1    Mouthon, L.2    Mahr, A.3
  • 30
    • 0036845156 scopus 로고    scopus 로고
    • Predictors and outcomes of scleroderma renal crisis: The high dose versus low-dose of penicillamine in early diffuse systemic sclerosis trial
    • DeMarco PJ, Weisman MH, Seibold JR, et al. Predictors and outcomes of scleroderma renal crisis: the high dose versus low-dose of penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002; 46: 2983-2989.
    • (2002) Arthritis Rheum , vol.46 , pp. 2983-2989
    • DeMarco, P.J.1    Weisman, M.H.2    Seibold, J.R.3
  • 31
    • 0024465792 scopus 로고
    • Normotensive renal failure in systemic sclerosis
    • Helfrich DJ, Banner B, Steen VD, et al. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32: 1128-1134.
    • (1989) Arthritis Rheum , vol.32 , pp. 1128-1134
    • Helfrich, D.J.1    Banner, B.2    Steen, V.D.3
  • 32
    • 0036225585 scopus 로고    scopus 로고
    • Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis
    • Giacomelli R, Valentini G, Salsano F, et al. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. J Rheumatol 2002; 29: 731-736.
    • (2002) J Rheumatol , vol.29 , pp. 731-736
    • Giacomelli, R.1    Valentini, G.2    Salsano, F.3
  • 33
    • 33845867399 scopus 로고    scopus 로고
    • Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience in one centre
    • Beretta L, Caronni M, Raimondi M, et al. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre. Clin Rheumatol 2007; 26: 168-172.
    • (2007) Clin Rheumatol , vol.26 , pp. 168-172
    • Beretta, L.1    Caronni, M.2    Raimondi, M.3
  • 34
    • 0036843172 scopus 로고    scopus 로고
    • Systemic sclerosis and interstitial lung disease: A pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function
    • Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. J Rheumatol 2002; 29: 2371-2378.
    • (2002) J Rheumatol , vol.29 , pp. 2371-2378
    • Griffiths, B.1    Miles, S.2    Moss, H.3
  • 35
    • 33846333911 scopus 로고    scopus 로고
    • Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease
    • Yiannopoulos G, Pastromas V, Antonopoulos I, et al. Combination of intravenous pulses of cyclophosphamide and methylprednisolone in patients with systemic sclerosis and interstitial lung disease. Rheumatol Int 2007; 27: 357-361.
    • (2007) Rheumatol Int , vol.27 , pp. 357-361
    • Yiannopoulos, G.1    Pastromas, V.2    Antonopoulos, I.3
  • 36
    • 78649502678 scopus 로고    scopus 로고
    • Immunotherapy of systemic sclerosis
    • Manno R, Boin F. Immunotherapy of systemic sclerosis. Immunotherapy 2010; 2: 863-878.
    • (2010) Immunotherapy , vol.2 , pp. 863-878
    • Manno, R.1    Boin, F.2
  • 37
    • 34848833579 scopus 로고    scopus 로고
    • B cell infiltration in systemic sclerosis-associated interstitial lung disease
    • Lafyatis R, O'Hara C, Feghali-Bostwick CA, et al. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum 2007; 56: 3167-3168.
    • (2007) Arthritis Rheum , vol.56 , pp. 3167-3168
    • Lafyatis, R.1    O'Hara, C.2    Feghali-Bostwick, C.A.3
  • 38
    • 43049159803 scopus 로고    scopus 로고
    • Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab
    • McGonagle D, Tan AL, Madden J, et al. Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab. Rheumatology 2008; 47: 552-553.
    • (2008) Rheumatology , vol.47 , pp. 552-553
    • McGonagle, D.1    Tan, A.L.2    Madden, J.3
  • 39
    • 77957019831 scopus 로고    scopus 로고
    • Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature
    • Daoussis D, Liossis SN, Tsamandas AC, et al. Is there a role for B-cell depletion as therapy for scleroderma? A case report and review of the literature. Semin Arthritis Rheum 2010; 40: 127-136.
    • (2010) Semin Arthritis Rheum , vol.40 , pp. 127-136
    • Daoussis, D.1    Liossis, S.N.2    Tsamandas, A.C.3
  • 40
    • 84863300540 scopus 로고    scopus 로고
    • Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab
    • Yoo WH. Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab. Rheumatol Int 2012; 32: 795-798.
    • (2012) Rheumatol Int , vol.32 , pp. 795-798
    • Yoo, W.H.1
  • 41
    • 73449095775 scopus 로고    scopus 로고
    • Rituximab in diffuse cutaneous systemic sclerosis: An open label clinical and histopatological study
    • Smith V, Van Praet JT, Vandooren B, et al. Rituximab in diffuse cutaneous systemic sclerosis: an open label clinical and histopatological study. Ann Rheum Dis 2010; 69: 193-197.
    • (2010) Ann Rheum Dis , vol.69 , pp. 193-197
    • Smith, V.1    van Praet, J.T.2    Vandooren, B.3
  • 42
    • 59649109772 scopus 로고    scopus 로고
    • B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis
    • Layaftis R, Kissin E, York M, et al. B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheum 2009; 60: 578-583.
    • (2009) Arthritis Rheum , vol.60 , pp. 578-583
    • Layaftis, R.1    Kissin, E.2    York, M.3
  • 43
    • 77950443096 scopus 로고    scopus 로고
    • Experience with rituximab in scleroderma: Results from a 1-year, proof-of-principle study
    • Daoussis D, Liossis SN, Tsamandas AC, et al. Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study. Rheumatology 2010; 49: 271-280.
    • (2010) Rheumatology , vol.49 , pp. 271-280
    • Daoussis, D.1    Liossis, S.N.2    Tsamandas, A.C.3
  • 44
    • 84867383069 scopus 로고    scopus 로고
    • Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis
    • Daoussis D, Liossis SN, Tsmandas AC, et al. Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis. Clin Exp Rheum 2012; 30: 17-22.
    • (2012) Clin Exp Rheum , vol.30 , pp. 17-22
    • Daoussis, D.1    Liossis, S.N.2    Tsmandas, A.C.3
  • 45
    • 77956992383 scopus 로고    scopus 로고
    • B cell depletion in diffuse progressive systemic sclerosis: Safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial
    • Bosello S, De Santis M, Lama G, et al. B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
    • (2010) Arthritis Res Ther , vol.12
    • Bosello, S.1    de Santis, M.2    Lama, G.3
  • 46
    • 84865814629 scopus 로고    scopus 로고
    • Severe interstitial lung disease in connective tissue disease: Rituximab as rescue therapy
    • Keir GJ, Maher TM, Hansell DM, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012; 40: 641-648.
    • (2012) Eur Respir J , vol.40 , pp. 641-648
    • Keir, G.J.1    Maher, T.M.2    Hansell, D.M.3
  • 47
    • 34447503592 scopus 로고    scopus 로고
    • Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease
    • Lam GK, Hummers LK, Woods A, et al. Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease. J Rheumatol 2007; 34: 1636-1637.
    • (2007) J Rheumatol , vol.34 , pp. 1636-1637
    • Lam, G.K.1    Hummers, L.K.2    Woods, A.3
  • 48
    • 69949138488 scopus 로고    scopus 로고
    • An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis
    • Denton CP, Engelhart M, Tvede N, et al. An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis. Ann Rheum Dis 2009; 68: 1433-1439.
    • (2009) Ann Rheum Dis , vol.68 , pp. 1433-1439
    • Denton, C.P.1    Engelhart, M.2    Tvede, N.3
  • 49
    • 84878404903 scopus 로고    scopus 로고
    • Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: A EUSTAR observational study
    • Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2012; 72: 1217-1220.
    • (2012) Ann Rheum Dis , vol.72 , pp. 1217-1220
    • Elhai, M.1    Meunier, M.2    Matucci-Cerinic, M.3
  • 50
    • 77956631231 scopus 로고    scopus 로고
    • Evidence-based management of rapidly progressing systemic sclerosis
    • Khanna D, Denton CP. Evidence-based management of rapidly progressing systemic sclerosis. Best Pract Res Clin Rheumatol 2010; 24: 387-400.
    • (2010) Best Pract Res Clin Rheumatol , vol.24 , pp. 387-400
    • Khanna, D.1    Denton, C.P.2
  • 51
    • 0142023807 scopus 로고    scopus 로고
    • Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders
    • Tyndall A, Matucci-Cerinic M. Haematopoietic stem cell transplantation for the treatment of systemic sclerosis and other autoimmune disorders. Expert Opin Biol Ther 2003; 3: 1041-1049.
    • (2003) Expert Opin Biol Ther , vol.3 , pp. 1041-1049
    • Tyndall, A.1    Matucci-Cerinic, M.2
  • 52
    • 0035017415 scopus 로고    scopus 로고
    • Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: Procedure related mortality and impact on skin disease
    • Binks M, Passweg JR, Furst D, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 2001; 60: 577-584.
    • (2001) Ann Rheum Dis , vol.60 , pp. 577-584
    • Binks, M.1    Passweg, J.R.2    Furst, D.3
  • 53
    • 3242658935 scopus 로고    scopus 로고
    • Autologous stem cell transplantation in the treatment of systemic sclerosis: Report from the EBMT/EULAR Registry
    • Farge D, Passweg J, van Laar JM, et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 974-981.
    • (2004) Ann Rheum Dis , vol.63 , pp. 974-981
    • Farge, D.1    Passweg, J.2    van Laar, J.M.3
  • 54
    • 34548013337 scopus 로고    scopus 로고
    • High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: Long-term follow-up of the US multicenter pilot study
    • Nash RA, McSweeney PA, Crofford LJ, et al. High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-1396.
    • (2007) Blood , vol.110 , pp. 1388-1396
    • Nash, R.A.1    McSweeney, P.A.2    Crofford, L.J.3
  • 55
    • 84875236160 scopus 로고    scopus 로고
    • The ASTIS trial: Autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results
    • Van Laar JM, Farge D, Sont JK, et al. The ASTIS trial: autologous stem cell transplantation versus IV pulse cyclophosphamide in poor prognosis systemic sclerosis, first results. Ann Rheum Dis 2012; 71: 151.
    • (2012) Ann Rheum Dis , vol.71 , pp. 151
    • van Laar, J.M.1    Farge, D.2    Sont, J.K.3
  • 56
    • 67649671982 scopus 로고    scopus 로고
    • Pulmonary complications: One of the most challenging complications of systemic sclerosis
    • Wells AU, Steen V, Valentini G. Pulmonary complications: one of the most challenging complications of systemic sclerosis. Rheumatology 2009; 48: iii40-iii44.
    • (2009) Rheumatology , vol.48
    • Wells, A.U.1    Steen, V.2    Valentini, G.3
  • 57
    • 34249886274 scopus 로고    scopus 로고
    • Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis
    • Shah RM, Jimenez S, Wechsler R. Significance of ground-glass opacity on HRCT in long-term follow-up of patients with systemic sclerosis. J Thorac Imaging 2007; 22: 120-124.
    • (2007) J Thorac Imaging , vol.22 , pp. 120-124
    • Shah, R.M.1    Jimenez, S.2    Wechsler, R.3
  • 58
    • 0037098050 scopus 로고    scopus 로고
    • Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome
    • Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002; 165: 1581-1586.
    • (2002) Am J Respir Crit Care Med , vol.165 , pp. 1581-1586
    • Bouros, D.1    Wells, A.U.2    Nicholson, A.G.3
  • 59
    • 2642535906 scopus 로고    scopus 로고
    • Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis
    • Yanaba K, Hasegawa M, Takehara K, et al. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis. J Rheumatol 2004; 31: 1112-1120.
    • (2004) J Rheumatol , vol.31 , pp. 1112-1120
    • Yanaba, K.1    Hasegawa, M.2    Takehara, K.3
  • 60
    • 37849030474 scopus 로고    scopus 로고
    • Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease
    • Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008; 177: 91-98.
    • (2008) Am J Respir Crit Care Med , vol.177 , pp. 91-98
    • Strange, C.1    Bolster, M.B.2    Roth, M.D.3
  • 61
    • 78449269444 scopus 로고    scopus 로고
    • The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease
    • Wells AU. The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev 2010; 19: 237-241.
    • (2010) Eur Respir Rev , vol.19 , pp. 237-241
    • Wells, A.U.1
  • 62
    • 0021256105 scopus 로고
    • The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes
    • Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85: 751-758.
    • (1984) Chest , vol.85 , pp. 751-758
    • Mahler, D.A.1    Weinberg, D.H.2    Wells, C.K.3
  • 63
    • 0018119862 scopus 로고
    • Scleroderma (progressive systemic sclerosis) progress and course based on a personal series of 118 cases
    • Barnett AJ. Scleroderma (progressive systemic sclerosis) progress and course based on a personal series of 118 cases. Med J Aust 1978; 2: 129-134.
    • (1978) Med J Aust , vol.2 , pp. 129-134
    • Barnett, A.J.1
  • 64
    • 0021867044 scopus 로고
    • The effect of D-penicillamine on pulmonary findings in systemic sclerosis
    • Steen VD, Owens GR, Redmond C, et al. The effect of D-penicillamine on pulmonary findings in systemic sclerosis. Arthritis Rheum 1985; 28: 882-888.
    • (1985) Arthritis Rheum , vol.28 , pp. 882-888
    • Steen, V.D.1    Owens, G.R.2    Redmond, C.3
  • 65
    • 0031691662 scopus 로고    scopus 로고
    • African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease
    • Greidinger EL, Flaherty KT, White B, et al. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest 1998; 114: 801-807.
    • (1998) Chest , vol.114 , pp. 801-807
    • Greidinger, E.L.1    Flaherty, K.T.2    White, B.3
  • 66
    • 77956477550 scopus 로고    scopus 로고
    • Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort
    • Assassi S, Sharif R, Lasky RE, et al. Predictors of interstitial lung disease in early systemic sclerosis: a prospective longitudinal study of the GENISOS cohort. Arthritis Res Ther 2010; 12: R166.
    • (2010) Arthritis Res Ther , vol.12
    • Assassi, S.1    Sharif, R.2    Lasky, R.E.3
  • 67
    • 33747894351 scopus 로고    scopus 로고
    • Scleroderma lung: Initial forced vital capacity as predictor of pulmonary function decline
    • Plastiras SC, Karadimitrakis SP, Ziakas PD, et al. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline. Arthritis Rheum 2006; 55: 598-602.
    • (2006) Arthritis Rheum , vol.55 , pp. 598-602
    • Plastiras, S.C.1    Karadimitrakis, S.P.2    Ziakas, P.D.3
  • 68
    • 80053479089 scopus 로고    scopus 로고
    • Clinical course of lung physiology in patients with scleroderma and interstitial lung disease
    • Khanna D, Tseng CH, Farmani N, et al. Clinical course of lung physiology in patients with scleroderma and interstitial lung disease. Arthritis Rheum 2011; 63: 3078-3085.
    • (2011) Arthritis Rheum , vol.63 , pp. 3078-3085
    • Khanna, D.1    Tseng, C.H.2    Farmani, N.3
  • 69
    • 44449152061 scopus 로고    scopus 로고
    • Interstitial lung disease in systemic sclerosis: A simple staging system
    • Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med 2008; 177: 1248-1254.
    • (2008) Am J Respir Crit Care Med , vol.177 , pp. 1248-1254
    • Goh, N.S.1    Desai, S.R.2    Veeraraghavan, S.3
  • 70
    • 84874106886 scopus 로고    scopus 로고
    • Immunosuppression for interstitial lung disease in systemic sclerosis-novel insights and opportunities for translational research
    • Canadian Scleroderma Research Group
    • Hudson M, Steele R, Canadian Scleroderma Research Group, et al. Immunosuppression for interstitial lung disease in systemic sclerosis-novel insights and opportunities for translational research. J Cell Commun Signal 2012; 6: 187-190.
    • (2012) J Cell Commun Signal , vol.6 , pp. 187-190
    • Hudson, M.1    Steele, R.2
  • 71
    • 80052334244 scopus 로고    scopus 로고
    • Predicting treatment outcomes and responder subsets in sclerodermarelated interstitial lung disease
    • Roth MD, Tseng CH, Clements PJ, et al. Predicting treatment outcomes and responder subsets in sclerodermarelated interstitial lung disease. Arthritis Rheum 2011; 63: 2797-2808.
    • (2011) Arthritis Rheum , vol.63 , pp. 2797-2808
    • Roth, M.D.1    Tseng, C.H.2    Clements, P.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.